#AACR26 Junshi reports PD‑1×VEGF antibody in MSS colorectal cancer
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
Over 22,000 attendees and more than 7,400 abstracts, including a record 265 clinical trial abstracts. This section collects on-site analysis across fifteen signal directions, plus late-breaking, clinical-trial and new-drug abstracts.
Minhua Chu@chuminhua432Score6060 Minhua Chu@chuminhua432Score6060 #AACR26 Junshi reports PD‑1×VEGF + CTLA‑4 combo in HCC
Minhua Chu@chuminhua432Score6060 Raffaele Di Giacomo, PhD@sciqstScore6060 Heat 22 likes0 replies0 repostsIngo Hartung@HartungIngoScore6060 Heat 7765 likes1 reply11 repostsYakup Ergün@dr_yakupergunScore6060 AACR@AACRScore6060 Heat 1813 likes1 reply4 repostsAnu R I@anu_irisScore6060 Heat 11 like0 replies0 repostsDaniel Auclair@AuclairDanScore6060 Daniel Auclair@AuclairDanScore6060 Great session today at #AACR26 on NCI Human Tumor Atlas Network (HTAN).
Heat 1413 likes0 replies1 repostNaoto T Ueno, MD, PhD@teamoncologyScore6060 Inflammatory breast cancer (IBC) at #AACR26 is not just aggressive—it’s a systems disease.
Heat 2519 likes1 reply5 repostsRick Buck@Rick__BuckScore6060 Heat 54 likes0 replies1 repostAACR@AACRScore6060 Heat 118 likes0 replies3 repostsAnu R I@anu_irisScore6060 Interesting Updates on #KRAS inhibitors from
Moffitt Cancer Center@MoffittNewsScore6060 After her education session at #AACR26, we caught up with Jessica Islam, PhD (
Heat 1813 likes0 replies5 repostsAACR@AACRScore6060 Heat 31 like0 replies2 repostsaacr.orgScore6060 The Dark Side of Cancer Therapies - And Potential Solutions
Sheila A. Stewart (Washington University in St. Louis) on chemotherapy-induced peripheral neuropathy: about 70% of patients on chemotherapy experience it, and 20-30% have symptoms that last their whole lives.
No engagement yetAACR@AACRScore6060 Heat 62 likes1 reply3 repostsBB@0090bbScore6060 Is the live stream cutting out due to an issue on my end? #AACR26
Heat 10 likes1 reply0 repostsOriol Mirallas MD@DrMirallasScore6060 Oriol Mirallas MD@DrMirallasScore6060 NonsparseOncologist@5_utrScore6060 Heat 43 likes0 replies1 repostLUNGevity Foundation@LUNGevityScore6060 Heat 117 likes1 reply3 repostsAACR@AACRScore6060 Heat 53 likes0 replies2 repostsRick Buck@Rick__BuckScore6060 Here is our onsite preview edition of
Heat 65 likes0 replies1 repostHeather K. Beasley, PhD@HKbeasleyScore6060 Heat 11 like0 replies0 repostsAACR@AACRScore6060 Heat 1916 likes0 replies3 repostsONCO BRUNO@brunolarvolScore6060 Heat 77 likes0 replies0 repostsNonsparseOncologist@5_utrScore6060 92% DCR in pancreatic cancer. Extraordinary. Also meaningless. Here’s why DCR needs to die. #AACR26
Heat 4031 likes6 replies3 repostsAACR@AACRScore6060 Heat 00 likes0 replies0 reposts